1. Gass JD, Guerry RK, Jack RL, Harris G. Choroidal osteoma. Arch Ophthalmol.1978;96:428-435
2. Shields CL, Sun H, Demirci H, Shields JA. Factors predictive of tumor growth, tumor decalcification, choroidal neovascularization, and visual outcome in 74 eyes with choroidal osteoma. Arch. Ophthalmol. 2005;123:1658-1666.
3. Aylward GW, Chang TS, Pautler SE, Gass JD. A long-term follow-up of choroidal osteoma. Arch Ophthalmol. 1998;116:1337-1341.
4. Alameddine RM, Mansour AM, Kahtani E. Review of choroidal osteomas. Middle East African Journal of Ophthalmology, 2014,21(3):244-250.
5. Sharma S, Sribhargava N, Shanmugam MP. Choroidal neovascular membrane associated with choroidal osteoma (CO) treated with trans-pupillary thermotherapy. Indian J Ophthalmol. 2004;52:329e330.
6. Foster BS, Fernandez-Suntay JP, Dryja TP, Jakobiec FA, D’Amico DJ. Surgical removal and histopathologic findings of a subfoveal neovascular membrane associated with choroidal osteoma. Arch. Ophthalmol. 2003;121:273e276.
7. Jang JH, Kim KH, Lee SJ, Park JM. Photodynamic therapy combined with intravitreal bevacizumab in a patient with choroidal neovascularization secondary to choroidal osteoma. Korean J Ophthalmol KJO. 2012;26:478e480.
8. Mansour AM, Arevalo JF, Al Kahtani E, et al. Role of intravitreal antivascular endothelial growth factor injections for choroidal neovascularization due to choroidal osteoma. J Ophthalmol. 2014;2014:210458.
9. Agarwal M, Kantha M, Mayor R, Venkatesh R, Shroff CM. Bilateral choroidal osteoma with choroidal neovascular membrane treated with bevacizumab in a child. Middle East Afr J Ophthalmol. 2014;21:265-267.
10. S. Zafar et al. Intravitreal ranibizumab for treatment of choroidal neovascularization secondary to a bilateral choroidal osteoma. American Journal of Ophthalmology Case Reports 4 (2016) 7-10
11. Papastefanou VP, Pefkianaki M, Al Harby L, Arora AK, Cohen VM, Andrews RM, Sagoo MS. Intravitreal bevacizumab monotherapy for choroidal neovascularisation secondary to choroidal osteoma. Eye (Lond). 2016 Jun;30(6):843-9.
12. Ahmadieh H, Vafi N. Dramatic response of choroidal neovascularization associated with choroidal osteoma to the intravitreal injection of bevacizumab(Avastin). Graefe’s Arch. Clin Exp Ophthalmol. 2007;245:1731e1733.
13. Lekha T, Renuka N, Prasad H. Anti-vascular Endothelial Growth Factors for Choroidal Neovascularization Secondary to Choroidal Osteoma: Long-term Results. Oman J Ophthalmol.2015,Sep-Dec;8(3):185-7.
14. Behera M, Das MK. A case of choroidal osteoma in a 10-year-old child. Int Med Case Rep J. 2015;8:273e275.
15. Khan MA, DeCroos FC, Storey PP, Shields JA, Garg SJ, Shields CL. Outcomes of anti-vascular endothelial growth factor therapy in the management of choroidal neovascularization associated with choroidal osteoma. Retina. 2014; 34(9):1750-6.
16. Yoshikawa T, Takahashi K. Long-term outcomes of intravitreal injection of bevacizumab for choroidal neovascularization associated with choroidal osteoma.Clin Ophthalmol. 2015; 9: 429–437.
17. Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med. 2003; 9: 47–52.
18. Saitta A, Nicolai M, Neri P, Reibaldi M, Giovannini A, Mariotti C. Rescue therapy with intravitreal aflibercept for choroidal neovascularization secondary to choroidal osteoma non-responder to intravitreal bevacizumab and ranibizumab. International Ophthalmology. 2015,35(3):441-444.
19. Silva RP, Alencar LD, Júnior CAM, Moreira-Neto C. Choroidal Osteoma with Neovascular Membrane Managed with Aflibercept and Yellow Laser. JOJ Ophthal. 2017; 4(4): 555641.
20. Wu Z, Zhou P, Li X, Wang H, Luo D, et al. Structural Characterization of a Recombinant Fusion Protein by Instrumental Analysis and Molecular Modeling. PLoS ONE. 2013; 8 (3) e57642.
21. Dias J, Andrade G, Novais E, Farah M, Rodrigues E. Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept. International Journal of Retina and Vitreous. 2016;2:3.
22. Liu K, Song Y, Xu G, Ye J, Wu Z, Liu X, Dong X, Zhang M, Xing Y, Zhu S, Chen X, Shen Y, Huang H, Yu L, Ke Z, Rosenfeld PJ, Kaiser PK, Ying G, Sun X, Xu X; PHOENIX study group.Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX study. Am J Ophthalmol. 2018 Aug 24. pii: S0002-9394(18)30478-1.
23. Yan M, Huang Z, Lian HY, Song YP, Chen X. Conbercept for treatment of choroidal neovascularization secondary to pathologic myopia.Acta Ophthalmol. 2018 Sep 5.
24. Bai Y, Nie H, Wei S, Lu X, Ke X, Ouyang X, Feng S.Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity.Br J Ophthalmol. 2018 Jul 20.
25. Falavarjani1 K, Nguyen AD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature.Eye. 2013; 27, 787–794.
26. Chang LK, Sarraf D. Tears of the retinal pigment epithelium: an old problem in a new era. Retina 2007; 27(5): 523–534.